Stress Urinary Incontinence
Conditions
Keywords
stress urinary incontinence, SUI, pelvic floor dysfunction
Brief summary
This is an open label, interventional, single arm, multi-clinic study where each adult female participant with stress urinary incontinence (SUI) serves as her own control (vaginal pessary use vs. no vaginal pessary).
Detailed description
The overall objectives of this clinical study are to demonstrate the effectiveness and safety of the Pippa Fitness Pessary (device) when self-administered and used in a home environment. Specifically, this study will evaluate the effectiveness of the Pippa Fitness Pessary by assessing reduction in urine leakage in up to 90 women with Stress Urinary Incontinence. Effectiveness will be assessed by percentage reduction in 1-hour pad weight gain, reduction of stress urinary incontinence episodes per day, and a quality-of-life questionnaire. The safety of the Pippa Fitness Pessary will be evaluated by assessing all adverse events, including the results of urinalysis and vaginal examination.
Interventions
DEVICEVaginal pessary
A reusable vaginal pessary for stress urinary incontinence
Sponsors
Liv Labs Inc.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Interventional multi-clinic study where each participant serves as her own control.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female, ≥18 years of age * Diagnosed with SUI by a physician using a cough stress test (positive test) * Confirmed Pippa Fitness Pessary fit in clinic by a physician or qualified clinician (e.g., Nurse Practitioner, Registered Nurse) * Have a \>3 month history of experiencing more than 3 episodes of SUI per week * English literacy sufficient to understand the nature of the study and sufficient to read and understand the informed consent form * Provision of a signed and dated informed consent form * Willingness to use the Pippa Fitness Pessary during the study and comply with study procedures * Willingness to forego use of any vaginal insert (e.g.: vaginal pessaries, bladder supports, estrogen rings, tampons, and menstrual cups) while the Pippa Fitness Pessary is in place * Willingness to cease use of any other form of urinary incontinence treatment for the duration of the study * Willingness and ability to interact with study staff by email, phone, text message and video conferencing software throughout study
Exclusion criteria
* Known urethral stricture, bladder neck contracture, spastic bladder, vesicoureteral reflux, bladder stones, and/or bladder tumors * Concurrent bladder specific medications (including beta agonists or anticholinergics) that affect urination and the use of any other prescription medication and/or over-the-counter medication and/or dietary supplements (including herbal supplements and those taken as teas) that affect urination, except in those instances where they are medically necessary and can be actively supported at a stable dosage throughout the active study period * Known prolapse beyond hymen or any POP-Q point \> 0 * Known hypersensitivity to silicone rubber * Pelvic floor surgery including anterior bladder repair and urethral slings * Vaginal, perineal, or uterine surgery, or abortion (spontaneous or induced) within the past 3 months * Any injectable treatments, or prior surgeries for incontinence * Class III Obesity (BMI \> 40.0 kg/m2) * Currently suffering from urinary tract or vaginal infection * Pregnant or planning to become pregnant within 3 months, or within 3 months postpartum * History of Toxic Shock Syndrome or consistent symptoms * Previously diagnosed with urge-predominant or mixed predominant urinary incontinence, functional incontinence, incontinence due to a central or spinal cord neurological condition (such as multiple sclerosis, neurogenic bladder, Parkinson's, spina bifida), insensate incontinence, or overflow incontinence * Screening laboratory values outside the reference range considered significant by the investigator which might impact the safety of the participant or outcome of the study * Unsuccessful fit assessment during screening * Any other reason the investigator decides the potential participant should not participate in the study * Self-reported difficulty emptying bladder * Difficulty inserting or wearing an intra-vaginal device
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants With Diagnosed Stress Urinary Incontinence (SUI) Who Achieved >50% Reduction of Urine Leakage With Intervention | From baseline to 24 days | A composite endpoint comprising of study participants achieving \>50% leak reduction with investigational device use (treatment) as compared to without investigational device use (baseline). The two components of the composite endpoint are 1) \>50% reduction in pad weight gain for the International Continence Society's standardized 1-hour pad weight test, conducted once with investigational device use and once without investigational device use; and/or 2) \>50% reduction in mean daily leak episodes during a participant-controlled home phase, comparing at least 7 days without investigational device use to at least 7 days with investigational device use. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Quality of Life at Baseline and 24 Days | 24 days | Change in Quality of Life as measured by the Incontinence Impact Questionnaire Short Form (IIQ-7) at baseline and after treatment. The IIQ-7 assesses the psychosocial impact of urinary incontinence in women, specifically physical activity, travel, social relationships and emotional health. A total score is calculated by taking the average score of each QoL attribute responded to (ranging from 0 to 3) and multiplying it by 33 1/3 to put it on a standardized scale of 0 to 100. Higher scores indicate a greater negative impact of incontinence on the individual's quality of life. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMelody A Roberts
Liv Labs Inc.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 7 Participants |
| Age, Continuous | 39.94 years STANDARD_DEVIATION 2.88 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 7 Participants |
| Region of Enrollment United States | 7 participants |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 7 |
| other Total, other adverse events | 3 / 7 |
| serious Total, serious adverse events | 0 / 7 |
Outcome results
None listed